Mehow Innovative Ltd. Class A

Mehow Innovative Ltd. Class A

SSZSE:301363
15.43
CNY
-0.92
(-5.63%)
0.39EPS
41.84P/E
12.93BMarket Cap
Apr 22Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.82
1.17
1.25
1.61
1.94
1.68
2
2.05
2.26
Basic EPS, GAAP
0.18
0.37
0.36
0.44
0.55
0.39
0.46
0.36
0.39
Free Cash Flow per Basic Share
0.15
0.17
0.09
-0.17
0.25
0.11
0.11
-0.14
- -
Dividend per Share
0.03
0.08
0.08
0.1
0.01
0.18
0.08
0.11
0.2
Book Value per Share
0.7
1.36
1.64
1.96
3.79
3.99
4.37
4.69
4.76
Tangible Book Value per Share
0.63
1.29
1.52
1.84
3.69
3.89
4.26
4.53
4.6
Basic Weighted Avg Shares
710
633
712
707
730
797
796
793
794
Sales/Revenue/Turnover
582
742
888
1,137
1,415
1,338
1,594
1,625
1,794
Operating Margin (%)
25.34
36.34
35.95
32.27
28.88
22.69
23.35
20.84
24.11
Depreciation Expense
22
24
25
45
71
89
99
106
- -
Net Income, GAAP
131
232
258
310
402
313
364
283
309
Effective Tax Rate (%)
12.16
12.43
12.22
10.93
11.95
10.85
11.33
12.82
14.11
Profit Margin (%)
22.5
31.31
29.05
27.26
28.41
23.42
22.82
17.42
17.2
Working Capital
337
706
634
675
2,118
2,087
2,088
2,025
2,096
LT Debt
- -
25
- -
90
4
12
9
3
3
Total Equity
500
965
1,167
1,392
3,021
3,182
3,480
3,733
3,785
Return on Invested Capital (%)
- -
31.9
24.67
23.58
17.77
10.09
10.92
7.75
- -
Return on Capital (%)
- -
31.63
24.07
23.13
17.84
10.06
10.87
7.74
- -
Return on Common Equity (%)
- -
31.73
24.19
24.24
18.22
10.1
10.92
7.85
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
109
108
115
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
796
796
796
Market Capitalization
14,466
14,590
12,934

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,461
2,442
2,553
Cash, Cash Equivalents & STI
1,662
1,596
1,623
Accounts Receivable, Net
364
378
462
Inventories
395
431
422
Total Current Liabilities
393
436
457
Payables & Accruals
- -
- -
- -
ST Debt
109
108
115
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
31.66%
7.29%
Free Cash Flow
- -
-164.97%
-228.7%
Net Income, GAAP
- -
4.34%
-22.18%
Sales/Revenue/Turnover
- -
13.64%
1.96%
Total Cash Common Dividend
- -
419.06%
30.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
282
425
450
438
1,594
2025
296
437
- -
431
1,625
2026
403
410
549
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.14
0.11
0.13
0.46
2025
0.06
0.08
- -
0.09
0.36
2026
0.07
0.09
0.14
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
- -
- -
0.06
0.11
2026
- -
0.14
0.01
- -
- -

Company Description

CEO
Xiao Chuan Xiong
Full Time Employees
3,101
Sector
Health technology
Industry
Medical specialties
Address
Shenzhen China
IPO Date
Oct 12, 2022
Business
Mehow Innovative Ltd. is a medical device contract development and manufacturing organization (CDMO) that provides integrated engineering, precision manufacturing, and assembly solutions for global healthcare, medical device, and life science companies. Founded in 2010 and headquartered in Shenzhen, China, the company operates primarily within the medical consumables, medical device components, and precision molding segments. Its core product and service offerings comprise respiratory health and sleep apnea management devices and subassemblies, including continuous positive airway pressure (CPAP) mask components, silicone cushions, humidification chambers, headgear interfaces, and exhalation valves; drug delivery and diabetes care systems, including continuous glucose monitoring (CGM) sensor housings, insulin pen components, wearable infusion sets, and auto-injector casings; in vitro diagnostic (IVD) consumables, microfluidic test chips, reagent cartridges, and sample handling vessels; cardiovascular and minimally invasive surgical device components, such as endoscopic structural parts, catheter connectors, and access trocars; and contract engineering services spanning high-precision mold design, liquid silicone rubber (LSR) molding, multi-shot plastic injection molding, cleanroom automated assembly, and regulatory compliance testing. In recent developments, the company has expanded its global manufacturing footprint by establishing and scaling operational capacity at its overseas production base in Malaysia, strengthening supply chain resilience for international original equipment manufacturer (OEM) clients across North America, Europe, and the Asia-Pacific region. Additionally, Mehow Innovative Ltd. has broadened its product pipeline by entering strategic development programs for next-generation GLP-1 drug delivery devices and advanced smart chronic disease management hardware, while continuing to upgrade automated production lines and high-standard cleanroom infrastructure across its manufacturing facilities.